Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.68 |
| ▸ | PGR | P06401 | 6/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.68 |
| ▸ | AR | P10275 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17603224 | 1.00 | NR3C1 (0.68) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL3279049 | 1.00 | NR3C1 (0.68) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL6406521 | 1.00 | NR3C1 (0.68) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL14437808 | 1.00 | NR3C1 (0.68) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL10942668 | 0.94 | NR3C1 (0.60) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL10942681 | 0.94 | NR3C1 (0.60) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL3275715 | 0.93 | NR3C1 (0.68) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL6408534 | 0.93 | NR3C1 (0.68) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL4982380 | 0.93 | NR3C1 (0.68) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL4979442 | 0.93 | NR3C1 (0.68) | NR3C1PGRNR3C2ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087412-A1 | Micronized Eplerenone Compositions | PFIZER INC | 2010-04-08 | — | — | US | disclosed |
| US-20070196471-A1 | Micronized Eplerenone Compositions | THOSAR SHILPA S | 2007-08-23 | — | — | US | disclosed |
| US-7157101-B2 | Micronized eplerenone compositions | G.D. SEARLE, LLC (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050192259-A1 | Aldosterone antagonist compositions for release during aldosterone acrophase | PHARMACIA CORPORATION | 2005-09-01 | — | — | US | disclosed |
| EP-1527782-A1 | Nanoparticulate eplerenone compositions | Pharmacia Corporation (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-1175220-B1 | NANOPARTICULATE EPLERENONE COMPOSITIONS | PHARMACIA CORP (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6863902-B2 | Mixture of methyl hydrogen 9,11 alpha-epoxy-17 alpha-hydroxy-3-oxopregn-4-ene-7-alpha, 21-dicarboxylate, gamma-lactone and carriers administered as aldosterone receptor antagonists, for prophylaxis of cardiovascular disorders | G. D. SEARLE & CO. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040192661-A1 | Micronized eplerenone compositions | G. D. SEARLE & CO. | 2004-09-30 | — | — | US | disclosed |
| US-20030215518-A1 | Immediate release eplerenone compositions | THOSAR SHILPA S (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030212053-A1 | Nanoparticulate eplerenone compositions | THOSAR SHILPA S (US) | 2003-11-13 | — | — | US | disclosed |
| EP-1135139-B1 | MICRONIZED EPLERENONE COMPOSITIONS | SEARLE & CO (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6592902-B2 | Aldosterone receptor blockers | THOSAR SHILPA S (US) | 2003-07-15 | — | — | US | disclosed |
| US-6558707-B1 | Micronized particles in carrier such as a purified, micro-crystalline or alkylated cellulose | G. D. SEARLE & CO. | 2003-05-06 | — | — | US | disclosed |
| US-6534093-B1 | Immediate release eplerenone compositions | G.D. SEARLE & CO. | 2003-03-18 | — | — | US | disclosed |
| US-6495165-B1 | PARTICLES OF PREGN-4-ENE-7,21-DICARBOXYLIC ACID, 9,11-EPOXY-17-HYDROXY-3-OXO-,GAMMA-LACTONE, METHYL ESTER(7,11,17-ALPHA) AND CARRIERS ADMINISTERED AS ALDOSTERONE RECEPTOR ANTAGONIST FOR PROPHYLAXIS OF CARDIOVASCULAR AND LIVER DISORDERS | G.D. SEARLE & CO. | 2002-12-17 | — | — | US | disclosed |
| US-20020136775-A1 | Controlled release eplerenone compositions | THOSAR SHILPA S (US) | 2002-09-26 | — | — | US | disclosed |
| US-20020132001-A1 | Aldosterone antagonist composition for release during aldosterone acrophase | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | disclosed |
| US-6410054-B1 | Immediate release eplerenone compositions | G. D. SEARLE & CO. | 2002-06-25 | — | — | US | disclosed |
| US-20020006919-A1 | Nanoparticulate eplerenone compositions | THOSAR SHILPA S (US) | 2002-01-17 | — | — | US | disclosed |
| US-4559332-A | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof | CIBA GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087412-A1 | Micronized Eplerenone Compositions | NR3C2, MC2R, PTGER1 | NR3C1 28/4885PGR 232/4885NR3C2 1/4885 |
| US-20030212053-A1 | Nanoparticulate eplerenone compositions | NR3C2, PTGER1, MC2R | NR3C1 16/4885PGR 527/4885NR3C2 1/4885 |
| US-20020006919-A1 | Nanoparticulate eplerenone compositions | NR3C2, PTGER1, MC2R | NR3C1 16/4885PGR 527/4885NR3C2 1/4885 |
| US-20030215518-A1 | Immediate release eplerenone compositions | MC2R, NR3C2, ADRB1 | NR3C1 19/4885PGR 218/4885NR3C2 2/4885 |
| US-20020132001-A1 | Aldosterone antagonist composition for release during aldosterone acrophase | NR3C2, MC2R, HSD11B2 | NR3C1 19/4885PGR 718/4885NR3C2 1/4885 |
| US-20020136775-A1 | Controlled release eplerenone compositions | MC2R, NR3C2, ADRB1 | NR3C1 24/4885PGR 167/4885NR3C2 2/4885 |
| US-20050192259-A1 | Aldosterone antagonist compositions for release during aldosterone acrophase | NR3C2, HSD11B1, HSD11B2 | NR3C1 21/4885PGR 728/4885NR3C2 1/4885 |
| US-20070196471-A1 | Micronized Eplerenone Compositions | NR3C2, MC2R, PTGER1 | NR3C1 28/4885PGR 232/4885NR3C2 1/4885 |
| US-20040192661-A1 | Micronized eplerenone compositions | NR3C2, MC2R, PTGER1 | NR3C1 28/4885PGR 232/4885NR3C2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.